Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA

Neuroscience Research

Volumn 53, Issue 3, 2005, Pages 241-249

  Wang, Yu Lai ^a,b   Liu, Wanzhao ^a,b   Wada, Etsuko ^a   Murata, Miho ^a,b   Wada, Keiji ^a,b   Kanazawa, Ichiro ^a,b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Gene therapy; HD mouse model (R6 2); Huntington's disease; Small interfering RNAs (siRNAs)

Indexed keywords

HUNTINGTIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN NERVE CELL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; LONGEVITY; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATE CORTEX; TRANSGENIC MOUSE;

ANIMALS; BODY WEIGHT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; HUNTINGTON DISEASE; INJECTIONS, INTRAVENTRICULAR; INTRANUCLEAR INCLUSION BODIES; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; RNA, SMALL INTERFERING; SURVIVAL RATE; TRANSGENES; TREATMENT OUTCOME; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 26844494370     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2005.06.021     Document Type: Article

References (37)

1. R.J. Boado, A. Kazantsev, B.L. Apostol, L.M. Thompson, and W.M. Pardridge Antisense-mediated down-regulation of the human huntingtin gene J. Pharmacol. Exp. Ther. 295 2000 239 243
2. A.J. Bridge, S. Pebernard, A. Ducraux, A.L. Nicoulaz, and R. Iggo Induction of an interferon response by RNAi vectors in mammalian cells Nat. Genet. 34 2003 263 264
3. A. Busch, S. Engemann, R. Lurz, H. Okazawa, H. Lehrach, and E.E. Wanker Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease J. Biol. Chem. 278 2003 41452 41461
4. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, J. Bian, L. Guo, L.A. Farrell, S.M. Hersch, W. Hobbs, J.P. Vonsattel, J.H. Cha, and R.M. Friedlander Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat. Med. 6 2000 797 801
5. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
6. I. Dragatsis, M.S. Levine, and S. Zeitlin Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice Nat. Genet. 26 2000 300 306
7. M.P. Duyao, A.B. Auerbach, A. Ryan, F. Persichetti, G.T. Barnes, S.M. McNeil, P. Ge, J.P. Vonsattel, J.F. Gusella, and A.L. Joyner Inactivation of the mouse Huntington's disease gene homolog Hdh Science 269 1995 407 410
8. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N.W. Kowall, R.R. Ratan, R. Luthi-Carter, and S.M. Hersch Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J. Neurosci. 23 2003 9418 9427
9. S. Gines, I.S. Seong, E. Fossale, E. Ivanova, F. Trettel, J.F. Gusella, V.C. Wheeler, F. Persichetti, and M.E. MacDonald Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice Hum. Mol. Genet. 12 2003 497 508
10. J.F. Gusella, and M.E. MacDonald Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease Nat. Rev. Neurosci. 1 2000 109 115
11. N.S. Haque, P. Borghesani, and O. Isacson Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder Mol. Med. Today 3 1997 175 183
12. S.Q. Harper, P.D. Staber, X. He, S.L. Eliason, I.H. Martins, Q. Mao, L. Yang, R.M. Kotin, H.L. Paulson, and B.L. Davidson From the Cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. U.S.A. 102 2005 5820 5825
13. N. Hazeki, T. Tsukamoto, I. Yazawa, M. Koyama, S. Hattori, I. Someki, T. Iwatsubo, K. Nakamura, J. Goto, and I. Kanazawa Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine Biochem. Biophys. Res. Commun. 294 2002 429 440
14. M.D. Kaytor, K.D. Wilkinson, and S.T. Warren Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity J. Neurochem. 89 2004 962 973
15. L. Kennedy, E. Evans, C.M. Chen, L. Craven, P.J. Detloff, M. Ennis, and P.F. Shelbourne Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis Hum. Mol. Genet. 12 2003 3359 3367
16. W. Liu, J. Goto, Y. Wang, M. Murata, K. Wada, and I. Kanazawa Specific inhibition of Huntington's disease gene expression by siRNAs in cultured cells Proc. Jpn. Acad. 79 Ser. B 2003 293 298
17. L. Mangiarini, K. Sathasivam, A. Mahal, R. Mott, M. Seller, and G.P. Bates Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation Nat. Genet. 15 1997 197 200
18. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506
19. L.B. Menalled, and M.F. Chesselet Mouse models of Huntington's disease Trends Pharmacol. Sci. 23 2002 32 39
20. J. Nasir, S.B. Floresco, J.R. O'Kusky, V.M. Diewert, J.M. Richman, J. Zeisler, A. Borowski, J.D. Marth, A.G. Phillips, and M.R. Hayden Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes Cell 81 1995 811 823
21. C. Nellemann, K. Abell, A. Norremolle, T. Lokkegaard, B. Naver, C. Ropke, J. Rygaard, S.A. Sorensen, and L. Hasholt Inhibition of Huntington synthesis by antisense oligodeoxynucleotides Mol. Cell Neurosci. 16 2000 313 323
22. C.D. Novina, M.F. Murray, D.M. Dykxhoorn, P.J. Beresford, J. Riess, S.K. Lee, R.G. Collman, J. Lieberman, P. Shankar, and P.A. Sharp siRNA-directed inhibition of HIV-1 infection Nat. Med. 8 2002 681 686
23. K. Obrietan, and K.R. Hoyt CRE-mediated transcription is increased in Huntington's disease transgenic mice J. Neurosci. 24 2004 791 796
24. K. Sakurai, S. Iizuka, J.S. Shen, X.L. Meng, T. Mori, A. Umezawa, T. Ohashi, and Y. Eto Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice Gene Ther. 11 2004 1475 1481
25. G. Schaffar, P. Breuer, R. Boteva, C. Behrends, N. Tzvetkov, N. Strippel, H. Sakahira, K. Siegers, M. Hayer-Hartl, and F.U. Hartl Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation Mol. Cell. 15 2004 95 105
26. J.S. Shen, X.L. Meng, T. Ohashi, and Y. Eto Adenovirus-mediated prenatal gene transfer to murine central nervous system Gene Ther. 9 2002 819 823
27. J.S. Shen, K. Watabe, T. Ohashi, and Y. Eto Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements Gene Ther. 8 2001 1081 1087
28. E. Song, S.K. Lee, D.M. Dykxhoorn, C. Novina, D. Zhang, K. Crawford, J. Cerny, P.A. Sharp, J. Lieberman, N. Manjunath, and P. Shankar Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages J. Virol. 77 2003 7174 7181
29. D.J. Stephan, Z.Y. Yang, H. San, R.D. Simari, C.J. Wheeler, P.L. Felgner, D. Gordon, G.J. Nabel, and E.G. Nabel A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo Hum. Gene Ther. 7 1996 1803 1812
30. K.L. Sugars, R. Brown, L.J. Cook, J. Swartz, and D.C. Rubinsztein Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis J. Biol. Chem. 279 2004 4988 4999
31. M. Tanaka, Y. Machida, S. Niu, T. Ikeda, N.R. Jana, H. Doi, M. Kurosawa, M. Nekooki, and N. Nukina Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease Nat. Med. 10 2004 148 154
32. E. Trushina, M.P. Heldebrant, C.M. Perez-Terzic, R. Bortolon, I.V. Kovtun, J.D. Badger 2nd, A. Terzic, A. Estevez, A.J. Windebank, R.B. Dyer, J. Yao, and C.T. McMurray Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease Proc. Natl. Acad. Sci. U.S.A. 100 2003 12171 12176
33. T. Tuschl Expanding small RNA interference Nat. Biotechnol. 20 2002 446 448
34. H. Xia, Q. Mao, S.L. Eliason, S.Q. Harper, I.H. Martins, H.T. Orr, H.L. Paulson, L. Yang, R.M. Kotin, and B.L. Davidson RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia Nat. Med. 10 2004 816 820
35. A. Yamamoto, J.J. Lucas, and R. Hen Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66
36. L. Yen, S.M. Strittmatter, and R.G. Kalb Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA Ann. Neurol. 46 1999 366 373
37. S. Zeitlin, J.P. Liu, D.L. Chapman, V.E. Papaioannou, and A. Efstratiadis Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue Nat. Genet. 11 1995 155 163